Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
30.63
-1.37 (-4.27%)
At close: Jun 5, 2025, 4:00 PM
31.00
+0.37 (1.21%)
After-hours: Jun 5, 2025, 4:58 PM EDT
Vera Therapeutics Employees
Vera Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 61 or 119.61% compared to the previous year.
Employees
112
Change (1Y)
61
Growth (1Y)
119.61%
Revenue / Employee
n/a
Profits / Employee
-$1,566,598
Market Cap
1.95B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112 | 61 | 119.61% |
Dec 31, 2023 | 51 | 5 | 10.87% |
Dec 31, 2022 | 46 | 29 | 170.59% |
Dec 31, 2021 | 17 | 9 | 112.50% |
Dec 31, 2020 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VERA News
- 1 day ago - Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 2 days ago - Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewsWire
- 3 days ago - Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data - Benzinga
- 3 days ago - Vera shares skyrocket as kidney disease drug succeeds in late-stage trial - Reuters
- 3 days ago - Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - GlobeNewsWire
- 21 days ago - Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug - Seeking Alpha
- 27 days ago - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire